Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Benzylhydrazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 3/20 | 0.90 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.85 |
| ▸ | MAPT | P10636 | 3/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzylhydrazine SCHEMBL697342 | 1.00 | IDO1 (0.90) | IDO1CYP3A4MAPTCYP1A2NFKB1 | |
| Benzylhydrazine SCHEMBL176979 | 0.95 | — | — | |
| Benzylhydrazine SCHEMBL27509884 | 0.92 | IDO1 (0.94) | IDO1CYP3A4MAPTCYP1A2NFKB1 | |
| Benzylhydrazine SCHEMBL28389744 | 0.92 | IDO1 (0.94) | IDO1CYP3A4MAPTCYP1A2NFKB1 | |
| Benzylhydrazine SCHEMBL27529745 | 0.92 | IDO1 (0.94) | IDO1CYP3A4MAPTCYP1A2NFKB1 | |
| Benzylhydrazine SCHEMBL8861708 | 0.92 | IDO1 (0.94) | IDO1CYP3A4MAPTCYP1A2NFKB1 | |
| Benzylhydrazine SCHEMBL176887 | 0.92 | CYP3A4 (1.00) | IDO1CYP3A4MAPTCYP1A2NFKB1 | |
| Benzylhydrazine SCHEMBL55982 | 0.92 | CYP3A4 (1.00) | IDO1CYP3A4MAPTCYP1A2NFKB1 | |
| Benzylhydrazine SCHEMBL10436051 | 0.92 | IDO1 (0.94) | IDO1CYP3A4MAPTCYP1A2NFKB1 | |
| Benzylhydrazine SCHEMBL29080870 | 0.90 | CYP3A4 (0.95) | IDO1CYP3A4MAPTCYP1A2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117881675-A | 2, 4-dihydro-3H-1, 2, 4-triazol-3-one P2X7 antagonists | 布雷耶疗法有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-11597702-B2 | Substituted pyrazoles FFA4/GPR120 receptor agonists | GOLGI NEUROSCIENCES S.R.L. (IT) | 2023-03-07 | — | — | US | disclosed |
| CN-108473502-B | 4, 6-dihydropyrrolo [3,4-C ] pyrazole-5 (1H) -carbonitrile derivatives for the treatment of cancer | 特殊治疗有限公司 | 2022-04-26 | — | — | CN | disclosed |
| US-11306096-B2 | 4,6 dihydropyrrolo [3,4-C] pyrazole-5 (1H)-carbonitrile derivates for treating cancer | MISSION THERAPEUTICS LIMITED (GB) | 2022-04-19 | — | — | US | disclosed |
| US-20210221813-A1 | 4,6 DIHYDROPYRROLO [3,4-C] PYRAZOLE-5 (1H)-CARBONITRILE DERIVATES FOR TREATING CANCER | MISSION THERAPEUTICS LIMITED (AE) | 2021-07-22 | — | — | US | disclosed |
| EP-3430012-B1 | 4,6-DIHYDROPYRROLO[3,4-C]PYRAZOLE-5(1H)-CARBONITRILE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LTD (GB) | 2021-06-16 | — | — | EP | disclosed |
| US-20210087148-A1 | SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS | GOLGI NEUROSCIENCES S.R.L. (IT) | 2021-03-25 | — | — | US | disclosed |
| EP-3430012-A1 | 4,6 DIHYDROPYRROLO [3,4-C]PYRAZOLE-5 (1H)-CARBONITRILE DERIVATES FOR TREATING CANCER | Mission Therapeutics Limited (GB) | 2019-01-23 | — | — | EP | disclosed |
| CN-108473502-A | 4, 6-dihydropyrrolo [3,4-C ] pyrazole-5 (1H) -carbonitrile derivatives for the treatment of cancer | 特殊治疗有限公司 | 2018-08-31 | — | — | CN | disclosed |
| WO-2017158381-A1 | 4,6 DIHYDROPYRROLO [3,4-C] PYRAZOLE-5 (1H)-CARBONITRILE DERIVATES FOR TRATING CANCER | MISSION THERAPEUTICS LIMITED (GB) | 2017-09-21 | — | — | WO | disclosed |
| EP-2421826-B1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-8163793-B2 | Proline derivatives | HOFFMAN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| EP-2421826-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| EP-2324028-A2 | THERAPEUTIC AGENTS 414 | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010121918-A1 | PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-10-21 | — | — | US | disclosed |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| WO-2010015849-A2 | THERAPEUTIC AGENTS 414 | ASTRAZENECA AB (SE) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087148-A1 | SUBSTITUTED PYRAZOLES FFA4/GPR120 RECEPTOR AGONISTS | FFAR4, FFAR3, FFAR1 | SLC6A2 1844/4885IDO1 2924/4885CYP3A4 841/4885 |
| US-20210221813-A1 | 4,6 DIHYDROPYRROLO [3,4-C] PYRAZOLE-5 (1H)-CARBONITRILE DERIVATES FOR TREATING CANCER | USP7, USP1, USP3 | SLC6A2 4685/4885IDO1 1045/4885CYP3A4 868/4885 |
| US-11306096-B2 | 4,6 dihydropyrrolo [3,4-C] pyrazole-5 (1H)-carbonitrile derivates for treating cancer | USP7, USP1, USP3 | SLC6A2 4685/4885IDO1 1045/4885CYP3A4 868/4885 |
| US-11597702-B2 | Substituted pyrazoles FFA4/GPR120 receptor agonists | FFAR4, FFAR3, FFAR1 | SLC6A2 1844/4885IDO1 2924/4885CYP3A4 841/4885 |
| US-20100093757-A1 | THERAPEUTIC AGENTS 414 | GCK, GCKR, GPR119 | SLC6A2 3028/4885IDO1 3277/4885CYP3A4 1716/4885 |
| US-20100267722-A1 | NOVEL PROLINE DERIVATIVES | PRAP1, PRR12, SLC6A7 | SLC6A2 1374/4885IDO1 1249/4885CYP3A4 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.